To test if PTC209 could effectively inhibit the growth of AR-positive prostate cancer and CRPC, we first examined the effect of PTC209 on cell proliferation in AR-positive PCa cell lines LNCaP, VCaP, C4-2, and 22Rv1, and observed a low IC50 (around 0.6 μM) (Supplementary Fig. 7). Here, AR is linked to posterior cortical atrophy.